



Trial design in IBD trials vs placebo


1 Randomized induction-only trials



2 Randomized maintenance-only trials



3 Responder re-randomization trials




4 Randomized treat-through trials



5 Umbrella trials

Multiple targeted therapies within one disease



IBD trials

CLASSIC I
ULTRA-1
ELEVATE-UC 12

ACCENT I&II
CLASSIC II
CHARM
PRECiSE 2
VISIBLE 1&2
LIBERTY-CD/UC

GEMINI I & II
PURSUIT
UNITI-->IM-UNITI
UNIFI
OCTAVE I&II-->Sustain
SELECTION
U-ACHIEVE-->U-ACCOMPLISH
U-EXCEL/U-EXCEED-->U-ENDURE
TRUE NORTH
ADVANCE & MOTIVATE--> FORTIFY
INSPIRE-->COMMAND
LUCENT
QUASAR

ACT 1&2
ULTRA 2
PRECiSE 1
ELEVATE UC 52
VIVID-1
GALAXI
GRAVITI
ASTRO

PIZZICATO
VIBRATO

Drug/Disease

Adalimumab-CD
Adalimumab-UC
Etrasimod-UC

Infliximab-CD
Adalimumab-CD
Adalimumab-CD
Certolizumab-CD
Vedolizumab Sc-UC/CD
Infliximab Sc-UC/CD

Vedolizumab-CD/UC
Golimumab-UC
Ustekinumab-CD
Ustekinumab-UC
Tofacitinib-UC
Filgotinib-UC
Upadacitinib-UC
Upadacitinib-CD
Ozanimod-UC
Risankizumab-CD
Risankizumab-UC
Mirikizumab-UC
Guselkumab-UC

Infliximab-UC
Adalimumab-UC
Certolizumab-CD
Etrasimod-UC
Mirikizumab-CD
Guselkumab-CD
Guselkumab Sc-CD
Guselkumab Sc-UC

Ritlecitinib-Brepocitinib-CD
Ritlecitinib-Brepocitinib-UC

